APO Research
Talk to an analyst

APO RESEARCH · REPORT

Resistant Pseudomonas Aeruginosa Infections Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchResistant Pseudomonas Aeruginosa Infections Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Resistant Pseudomonas Aeruginosa Infections Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Resistant Pseudomonas Aeruginosa Infections Drugs market include Achaogen Inc, AmpliPhi Biosciences Corp, Biolytics Pharma, ContraFect Corp, Inhibrx LP, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Shionogi & Co Ltd and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Resistant Pseudomonas Aeruginosa Infections Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Resistant Pseudomonas Aeruginosa Infections Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Resistant Pseudomonas Aeruginosa Infections Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Resistant Pseudomonas Aeruginosa Infections Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Company

Achaogen Inc

AmpliPhi Biosciences Corp

Biolytics Pharma

ContraFect Corp

Inhibrx LP

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Shionogi & Co Ltd

Novartis AG

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type

Cephalosporin

Lactam Drugs

Semi-Synthetic Penicillin

Others

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application

Hospital

Clinic

Home Care

Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Resistant Pseudomonas Aeruginosa Infections Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Resistant Pseudomonas Aeruginosa Infections Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Resistant Pseudomonas Aeruginosa Infections Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Resistant Pseudomonas Aeruginosa Infections Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Resistant Pseudomonas Aeruginosa Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Resistant Pseudomonas Aeruginosa Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Resistant Pseudomonas Aeruginosa Infections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Resistant Pseudomonas Aeruginosa Infections Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Resistant Pseudomonas Aeruginosa Infections Drugs industry.

Chapter 3: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Resistant Pseudomonas Aeruginosa Infections Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends Table 2. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers Table 3. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges Table 4. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints Table 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Company (2021-2026) Table 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Company, Product Type & Application Table 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cephalosporin Table 18. Significant Companies of Lactam Drugs Table 19. Significant Companies of Semi-Synthetic Penicillin Table 20. Significant Companies of Others Table 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type (2021-2026) Table 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Home Care Table 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application (2021-2026) Table 43. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application (2027-2032) Table 44. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2021-2026) Table 47. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2027-2032) Table 49. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Region (2021-2026) Table 52. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Region (2027-2032) Table 54. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2021-2026) Table 60. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2027-2032) Table 62. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Market Share by Country (2027-2032) Table 66. Achaogen Inc Company Information Table 67. Achaogen Inc Business Overview Table 68. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 70. Achaogen Inc Recent Development Table 71. AmpliPhi Biosciences Corp Company Information Table 72. AmpliPhi Biosciences Corp Business Overview Table 73. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 75. AmpliPhi Biosciences Corp Recent Development Table 76. Biolytics Pharma Company Information Table 77. Biolytics Pharma Business Overview Table 78. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 80. Biolytics Pharma Recent Development Table 81. ContraFect Corp Company Information Table 82. ContraFect Corp Business Overview Table 83. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 85. ContraFect Corp Recent Development Table 86. Inhibrx LP Company Information Table 87. Inhibrx LP Business Overview Table 88. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 90. Inhibrx LP Recent Development Table 91. LegoChem Biosciences Inc Company Information Table 92. LegoChem Biosciences Inc Business Overview Table 93. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 95. LegoChem Biosciences Inc Recent Development Table 96. Melinta Therapeutics Inc Company Information Table 97. Melinta Therapeutics Inc Business Overview Table 98. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 100. Melinta Therapeutics Inc Recent Development Table 101. Shionogi & Co Ltd Company Information Table 102. Shionogi & Co Ltd Business Overview Table 103. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 105. Shionogi & Co Ltd Recent Development Table 106. Novartis AG Company Information Table 107. Novartis AG Business Overview Table 108. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio Table 110. Novartis AG Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List Table 114. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Product Image Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2021-2032) & (K Units) Figure 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cephalosporin Image Figure 10. Lactam Drugs Image Figure 11. Semi-Synthetic Penicillin Image Figure 12. Others Image Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Home Care Image Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Cephalosporin
  • Lactam Drugs
  • Semi-Synthetic Penicillin
  • Others
Applications
  • Hospital
  • Clinic
  • Home Care
Companies covered
  • Achaogen Inc
  • AmpliPhi Biosciences Corp
  • Biolytics Pharma
  • ContraFect Corp
  • Inhibrx LP
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Shionogi & Co Ltd
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Dynamics
  1. 2.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends
  2. 2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers
  3. 2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges
  4. 2.4 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints
3 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Company
  1. 3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Ranking (2024-2026)
  6. 3.6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Product Type and Application
  8. 3.8 Global Resistant Pseudomonas Aeruginosa Infections Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Resistant Pseudomonas Aeruginosa Infections Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Type
  1. 4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Type Introduction
  2. 4.1.1 Cephalosporin
  3. 4.1.2 Lactam Drugs
  4. 4.1.3 Semi-Synthetic Penicillin
  5. 4.1.4 Others
  6. 4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type
  7. 4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type
  11. 4.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type (2021-2032)
5 Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application
  1. 5.1 Resistant Pseudomonas Aeruginosa Infections Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Home Care
  5. 5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application
  6. 5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application
  10. 5.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application (2021-2032)
6 Resistant Pseudomonas Aeruginosa Infections Drugs Regional Sales and Value Analysis
  1. 6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2027-2032)
  5. 6.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Country, 2025 VS 2032
7 Resistant Pseudomonas Aeruginosa Infections Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2027-2032)
  6. 7.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Achaogen Inc
  2. 8.1.1 Achaogen Inc Company Information
  3. 8.1.2 Achaogen Inc Business Overview
  4. 8.1.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  6. 8.1.5 Achaogen Inc Recent Developments
  7. 8.2 AmpliPhi Biosciences Corp
  8. 8.2.1 AmpliPhi Biosciences Corp Company Information
  9. 8.2.2 AmpliPhi Biosciences Corp Business Overview
  10. 8.2.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  12. 8.2.5 AmpliPhi Biosciences Corp Recent Developments
  13. 8.3 Biolytics Pharma
  14. 8.3.1 Biolytics Pharma Company Information
  15. 8.3.2 Biolytics Pharma Business Overview
  16. 8.3.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  18. 8.3.5 Biolytics Pharma Recent Developments
  19. 8.4 ContraFect Corp
  20. 8.4.1 ContraFect Corp Company Information
  21. 8.4.2 ContraFect Corp Business Overview
  22. 8.4.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  24. 8.4.5 ContraFect Corp Recent Developments
  25. 8.5 Inhibrx LP
  26. 8.5.1 Inhibrx LP Company Information
  27. 8.5.2 Inhibrx LP Business Overview
  28. 8.5.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  30. 8.5.5 Inhibrx LP Recent Developments
  31. 8.6 LegoChem Biosciences Inc
  32. 8.6.1 LegoChem Biosciences Inc Company Information
  33. 8.6.2 LegoChem Biosciences Inc Business Overview
  34. 8.6.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  36. 8.6.5 LegoChem Biosciences Inc Recent Developments
  37. 8.7 Melinta Therapeutics Inc
  38. 8.7.1 Melinta Therapeutics Inc Company Information
  39. 8.7.2 Melinta Therapeutics Inc Business Overview
  40. 8.7.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  42. 8.7.5 Melinta Therapeutics Inc Recent Developments
  43. 8.8 Shionogi & Co Ltd
  44. 8.8.1 Shionogi & Co Ltd Company Information
  45. 8.8.2 Shionogi & Co Ltd Business Overview
  46. 8.8.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  48. 8.8.5 Shionogi & Co Ltd Recent Developments
  49. 8.9 Novartis AG
  50. 8.9.1 Novartis AG Company Information
  51. 8.9.2 Novartis AG Business Overview
  52. 8.9.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
  54. 8.9.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Analysis
  2. 9.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Mode & Process
  6. 9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors
  9. 9.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst